Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India
Ranitidine Among 26 Drugs Dropped From NLEM 2022
Executive Summary
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
You may also be interested in...
What’s Next? Five Things To Look Out For In July
Generics Bulletin previews the most notable and anticipated events for July 2023.
Pretomanid Price Cut By 34% But Access Complexities Remain
Viatris, MedAccess and TB Alliance deal to lower the price of pretomanid, a key drug used as part of a shorter all-oral drug regime for multidrug-resistant TB, but country-level prioritization and uptake of the treatment option will be pivotal to widen access sharply.
Big Pharmas Trust To The Science In Zantac Lawsuits
Billions of dollars have been wiped off the value of big pharma stocks as the market finally woke up to widescale litigation concerning allegations of increased cancer risk associated with the use of ranitidine. Two companies, GSK and Sanofi, are confident that there is no link.